Baxter Recalls Vasopressin Injection Over CGMP Deviations

Baxter Healthcare Corporation initiated a recall of Vasopressin, in 0.9% Sodium Chloride Injection on August 6, 2026. The recall has been classified as Class II by the FDA. The affected product is Vasopressin in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), supplied in a 100 mL single-dose container under NDC 0338-9647-12. It is labeled for prescription use only and is sterile. The stated reason for the recall is CGMP deviations. Baxter Healthcare Corporation, based in Deerfield, Illinois, is the recalling firm. The recall status is listed as ongoing as of the reporting date. This action is documented under FDA recall event ID D-0819-2026. A Class II classification indicates a specific regulatory category assigned by the FDA to this recall event. No additional details about distribution scope or further corrective actions were included in the available record. This brief reflects only the information provided in the recall notice and does not characterize the clinical safety of vasopressin beyond the stated recall reason. Readers can consult the compound overview for more general context on vasopressin.